The increasing prevalence of multidrug-resistant pathogens such as methicillin-resistant Staphylococcus aureus (MRSA) underscores the need to develop novel strategies to treat life-threatening infections. We plan to develop an integrated platform to discover new pathways for antibacterials, new compounds to inhibit those pathways, rapid methods to identify molecular targets of promising compounds, and rational strategies to select compound-target pairs for further development. The platform has three aims focusing on S. aureus but can be extended to other pathogens. The objective ofthe Aim 1 is to identify cell envelope pathways that can be targeted by antibacterials. We are focusing on the cell envelope because defects in envelope integrity are frequently lethal in invivo. We will probe highly saturated transposon libraries with small molecules that have cell envelope targets and use Tn-seq to identify genes that drop out ofthe libraries. We will validate that these genes interact with the cell envelope targets being inhibited by the small molecules. With the Discovery & Translational Services (DTS) Core, we will analyze the fitness of validated mutant strains in animals to prioritize targets. The objective of the Aim 2 is to identify compounds that inhibit high priority targets (HPTs). We will use a novel cell-based, pathway-directed screening paradigm in which a panel of mutant strains are screened against the same compound library and compared to the wild type parent strain. One mutant strain will have a deletion in HPT while the others will have deletions in genes that have a synthetic lethal interaction with the HPT. Hits against the HPT will be identified as compounds that do not affect the growth of the wild type or AHPT strain, but inhibit growth in the other mutant strains. By using cell based pathway direct screens, we envision greatly shortening the lag between identifying possible antibacterial targets and discovering compounds that inhibit them. The objective of Aim 3 is to establish a strategy to define and select compound-target pairs for further development We will develop a phage-based transposition method to identify the specific targets of confirmed hits (from Aim 2) within the genetic interaction networks (defined in Aim 1). We will generate a pool of mutants that over-express, under-express, or have genes deleted across the entire genome, from which the specific molecular target can be inferred. Target mutations conferring resistance will be evaluated by comprehensive protein mutagenesis, and the most promising compound-target pairs will advance into antibacterial lead optimization with the DTS Core.

Public Health Relevance

Antibiotic-resistant infections pose a major threat to human health, with methicillin-resistant Staphylococcus aureus {MRSA) being among the most prevalent. The goal of this research is to establish an innovative platform to identify and prioritize new targets for antibacterial therapy, and to discover and optimize new compounds inhibiting those targets. The approach ultimately could lead to new treatments for MRSA infections and potentially be extended to other drug resistant bacterial pathogens.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program--Cooperative Agreements (U19)
Project #
5U19AI109764-05
Application #
9631909
Study Section
Special Emphasis Panel (ZAI1)
Program Officer
Maric, Maja
Project Start
Project End
Budget Start
2018-03-01
Budget End
2019-02-28
Support Year
5
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Harvard Medical School
Department
Type
DUNS #
047006379
City
Boston
State
MA
Country
United States
Zip Code
Baranowski, Catherine; Welsh, Michael A; Sham, Lok-To et al. (2018) Maturing Mycobacterium smegmatis peptidoglycan requires non-canonical crosslinks to maintain shape. Elife 7:
Rohs, Patricia D A; Buss, Jackson; Sim, Sue I et al. (2018) A central role for PBP2 in the activation of peptidoglycan polymerization by the bacterial cell elongation machinery. PLoS Genet 14:e1007726
Vickery, Christopher R; Wood, B McKay; Morris, Heidi G et al. (2018) Reconstitution of Staphylococcus aureus Lipoteichoic Acid Synthase Activity Identifies Congo Red as a Selective Inhibitor. J Am Chem Soc 140:876-879
Bertani, Blake R; Taylor, Rebecca J; Nagy, Emma et al. (2018) A cluster of residues in the lipopolysaccharide exporter that selects substrate variants for transport to the outer membrane. Mol Microbiol 109:541-554
Mandler, Michael D; Baidin, Vadim; Lee, James et al. (2018) Novobiocin Enhances Polymyxin Activity by Stimulating Lipopolysaccharide Transport. J Am Chem Soc 140:6749-6753
Sjodt, Megan; Brock, Kelly; Dobihal, Genevieve et al. (2018) Structure of the peptidoglycan polymerase RodA resolved by evolutionary coupling analysis. Nature 556:118-121
Zheng, Sanduo; Sham, Lok-To; Rubino, Frederick A et al. (2018) Structure and mutagenic analysis of the lipid II flippase MurJ from Escherichia coli. Proc Natl Acad Sci U S A 115:6709-6714
Rubino, Frederick A; Kumar, Sujeet; Ruiz, Natividad et al. (2018) Membrane Potential Is Required for MurJ Function. J Am Chem Soc 140:4481-4484
Schaefer, Kaitlin; Owens, Tristan W; Kahne, Daniel et al. (2018) Substrate Preferences Establish the Order of Cell Wall Assembly in Staphylococcus aureus. J Am Chem Soc 140:2442-2445
Sherman, David J; Xie, Ran; Taylor, Rebecca J et al. (2018) Lipopolysaccharide is transported to the cell surface by a membrane-to-membrane protein bridge. Science 359:798-801

Showing the most recent 10 out of 46 publications